30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)-Reference-Cited by-同舟云学术

30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)

Published:2018 Issue:4 Volume:3 Page:e000298
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

de Marinis Filippo,Ciardiello Fortunato,Baas Paul,Crinò Lucio,Giaccone Giuseppe,Grossi Francesco,Hellmann Matthew D.,Mok Tony S.K.,Lena Hervè,Paz-Ares Luis,Rodriguez-Abreu Delvys,Von Pavel Joachim,Gridelli Cesare

Funder

Italian Association of Thoracic Oncology

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference19 articles.

1. Cancer statistics, 2015

2. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy;Liao;Lung Cancer,2017

3. Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice;Passaro;Onco Targets Ther,2016

4. JCO Precision;Marchetti;Oncology,2017

5. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Neoadjuvant Radiotherapy on Survival in Patients with Stage IIIA-N2 Non-Small-Cell Lung Cancer Following Pneumonectomy;Journal of Clinical Medicine;2022-12-02

2. Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database;Frontiers in Oncology;2022-11-23

3. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma;Journal for ImmunoTherapy of Cancer;2022-03

4. Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle;Therapeutic Advances in Medical Oncology;2022-01

5. Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy;Cancers;2021-09-26